EPS (Diluted)Not reportedfor the trailing 12 months
Operating Cash Flow-$714Kn/m YoY
Source SEC Filings (10-K/10-Q)Latest period Q3 FY2023, ended Sep 30, 2023ReportedCurrency USDFYE December
Newest figures come from the 10-Q for Q3 FY2023, filed Nov 20, 2023.
Each column of the statement tables below links to the filing it was taken from.
This page shows ADHERA THERAPEUTICS INC (ATRX) financial statements, including the
income statement, balance sheet, cash flow statement, and key financial ratios.
View 13 years of annual fundamentals and quarterly data, with year-over-year
growth rates and compound annual growth rates (CAGR).
All figures are derived from SEC filings (10-K and 10-Q reports).
Rhea AIATRXFY2022
By FY2022, reported liabilities vastly exceeded assets, while the filings provide little current operating information.
The balance sheet shifted from FY2021 to FY2022 in a way that worsened financial coverage: assets fell 59.9%, while liabilities fell only 12.0%. With FY2022 current liabilities equal to total liabilities and equity at -$22.2M, the company was financed mainly by obligations rather than reported assets.
FY2021 is the latest year with both operating and cash-flow figures: an operating loss of $674K accompanied operating cash flow of -$665K, so cash broadly tracked the reported loss rather than showing a conversion cushion. Financing cash flow of $739K was positive that year, indicating funding activity—not operations—supplied the offset.
Some figures from recent filings were inconsistent and were omitted from this summary.
Financial Health Signals
Financial health score not available
ADHERA THERAPEUTICS INC does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The metrics below are current.
ADHERA THERAPEUTICS INC earned -$0.83 per diluted share (EPS) in Q3 2023.
Revenue
Not reported for Q3 2023.
EBITDA
Not reported for Q3 2023.
Net Income
Not reported for Q3 2023.
Cash & Balance Sheet
Cash & Debt
$32K
YoY-75.6%
QoQ-44.2%
5Y CAGR-65.4%
ADHERA THERAPEUTICS INC held $32K in cash as of Q3 2023; no long-term debt figure is on record for that period.
Shares Outstanding
7M
ADHERA THERAPEUTICS INC had 7M shares outstanding in Q3 2023.
Free Cash Flow
Not reported for Q3 2023.
Dividends Per Share
Not reported for Q3 2023.
Margins & Returns
None of these metrics is reported for Q3 2023.
Capital Allocation
None of these metrics is reported for Q3 2023.
ATRX Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
Not reported in any period shown, so not listed: Revenue, Cost of Revenue, Gross Profit, R&D Expenses, EBITDA, Interest Expense, Income Tax.
TTM is the trailing twelve months, Q4 FY2022 through Q3 FY2023, summed from the four most recent quarterly filings. A row marked — cannot be summed at all, because a quarter in the window reports no per-share figure; a row marked N/A could be summed, but a quarter in the window does not report that metric.
ATRX Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
Not reported in any period shown, so not listed: Long-Term Debt.
Not reported in any period shown, so not listed: Inventory, Accounts Receivable, Goodwill, Long-Term Debt.
ATRX Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
Not reported in any period shown, so not listed: Depreciation & Amortization, Capital Expenditures, Free Cash Flow, Investing Cash Flow.
TTM is the trailing twelve months, Q4 FY2022 through Q3 FY2023, summed from the four most recent quarterly filings. A row marked — cannot be summed at all, because a quarter in the window reports no per-share figure; a row marked N/A could be summed, but a quarter in the window does not report that metric.
ATRX Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
Not reported in any period shown, so not listed: Debt-to-Equity, FCF Margin.
Not reported in any period shown, so not listed: Gross Margin, Operating Margin, Net Margin, Return on Equity, Debt-to-Equity, Liabilities-to-Equity, Asset Turnover, FCF Margin.
Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Gross Margin, Operating Margin, Net Margin.
Note: Shareholder equity is negative (-$22.2M), which causes the debt-to-equity, liabilities-to-equity and return on equity ratios to appear negative or not meaningful. This can occur from accumulated losses or large share buyback programs.
Note: The current ratio is below 1.0 (0.00), indicating current liabilities exceed current assets, which may suggest potential short-term liquidity concerns.
ADHERA THERAPEUTICS INC (ATRX) had $79K in total assets as of fiscal year 2022, including both current and long-term assets.
Does ADHERA THERAPEUTICS INC buy back shares?
Yes, ADHERA THERAPEUTICS INC (ATRX) spent $2K on share buybacks during fiscal year 2022, returning capital to shareholders by reducing shares outstanding.
How many shares does ADHERA THERAPEUTICS INC have outstanding?
ADHERA THERAPEUTICS INC (ATRX) had 3M shares outstanding as of fiscal year 2022.
What is ADHERA THERAPEUTICS INC's current ratio?
ADHERA THERAPEUTICS INC (ATRX) had a current ratio of 0.00 as of fiscal year 2022, which is below 1.0, which may suggest potential liquidity concerns.
Why is ADHERA THERAPEUTICS INC's debt-to-equity ratio negative or not reported?
ADHERA THERAPEUTICS INC (ATRX) has negative shareholder equity of -$22.2M as of fiscal year 2022, so no debt-to-equity or liabilities-to-equity ratio is reported: dividing debt by equity that is not positive produces a number that cannot be read as leverage. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.